2016

Sartorius talks M&A as it looks to more than double revenues by 2025

27-Feb-2018 By Dan Stanton

Sartorius expects its Bioprocess Solutions Division to make €2.8bn ($3.4bn) annually by 2025 through a mix of organic growth and technology bolt-ons.

Correction

Repligen adding former Motorola plant in MA to filtration footprint

13-Feb-2018 By Dan Stanton

Repligen has leased a 64,000 square-foot facility in Massachusetts to where it will transfer production of its TangenX filtration products .

Room for another: Sandoz files Humira biosimilar in US

16-Jan-2018 By Dan Stanton

“There is room in most markets for a number of competitors” says Novartis as it submits its biosimilar adalimumab for review.

Second time the charm for Pfizer’s Epogen biosimilar in US

30-May-2017 By Dan Stanton

An advisory committee has recommended approval of Retacrit in the US after Pfizer addressed manufacturing and clinical concerns from its first submission in 2015.

update

US FDA warns Lonza about Walkersville site

25-Apr-2017 By Gareth Macdonald

The US FDA has warned Lonza about operations at its facility in Walkersville, Maryland, raising concerns about validation and aseptic process simulations.

Sartorius ups bioanalysis business with $320m Essen acquisition

03-Mar-2017 By Staff Reporter

Sartorius’ third acquisition in the bioanalysis space in the past year will add Essen BioScience’s real-time live-cell analysis platform to its portfolio.